Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection

Journal of Gene Medicine

Volumn 2, Issue 5, 2000, Pages 344-352

  Soler, M N ^a   Bobe P ^b   Benihoud, K ^c   Lemaire, G ^a   Roos, B A ^d   Lausson, S ^e  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CNRS   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Anticancer gene therapy; Medullary thyroid cancer; Nitric oxide synthase

Indexed keywords

CYTOMEGALOVIRUS;

DRUG DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NOS2 PROTEIN, RAT; NOS2A PROTEIN, HUMAN; PENICILLAMINE; RECOMBINANT DNA; S NITRO N ACETYLPENICILLAMINE; S-NITRO-N-ACETYLPENICILLAMINE;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; CYTOTOXICITY; DRUG EFFECT; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; LACTOSE OPERON; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PLASMID; RAT; RAT STRAIN; THYROID TUMOR;

ANIMALS; CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; DNA, RECOMBINANT; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LAC OPERON; NEOPLASM TRANSPLANTATION; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PENICILLAMINE; PLASMIDS; RATS; RATS, INBRED STRAINS; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0034280568     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-2254(200009/10)2:5<344::aid-jgm124>3.0.co;2-3     Document Type: Article

References (43)

1. Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 1994; 63: 175-195.
2. Drapier JC, Hibbs JB Jr. Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J Immunol 1988; 140: 2829-2838.
3. Tamir S, Tannenbaum SR. The role of nitric oxide (NO) in the carcinogenic process. Biochim Biophys Acta 1996; 1288: F31-F36.
4. Lepoivre M, Chenais B, Yapo A, et al. Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells. J Biol Chem 1990; 265: 14143-14149.
5. Burney S, Tamir S, Gal A, et al. A mechanism analysis of nitric oxide-induced cellular toxicity. Nitric Oxide 1997; 1: 130-144.
6. Kröncke KD, Brenner HH, Rodrigez ML, et al. Pancreatic islet cells are highly susceptible towards the cytotoxic effects of chemically generated nitric oxide. Biochim Biophys Acta 1993; 1182: 221-229.
7. Dong Z, O'Brian CA, Fidler IF. Activation of tumoricidal properties in macrophages by Iipopolysaccharide requires protein-tyrosine kinase activity. J Leukoc Biol 1993; 53: 53-60.
8. Hibbs JB Jr, Taintor RR, Vavrin Z. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987; 235: 473-476.
9. Hibbs JB Jr, Taintor RR, Vavrin Z, et al. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988; 157: 87-94.
10. Li L, Kilbourn RG, Adams J, et al. Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells. Cancer Res 1991; 51: 2531-2535.
11. Stuehr DJ, Nathan CF. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989; 169: 1543-1555.
12. Xie K, Dong ZY, Juang SH, et al. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995; 181: 1333-1343.
13. Xie K, Huang S, Dong Z, et al. Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst 1997; 89: 421-427.
14. Ruppert JM, Eggleston JC, deBustros A, et al. Disseminated calcitonin-poor medullary carcinoma in a patient with calcitonin-rich primary tumor. Am J Surg Pathol 1986; 10: 513-518.
15. Delisle MJ. Surveillance au long cours des cancers médullaires de la thyroide. Ann Endocrinol (Paris) 1988; 49: 51-60.
16. Hoefnagel CA, Delprat CC, Zanin D, et al. New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nuc Med 1988; 13: 159-165.
17. Saad MF, Guido JJ, Samaan NA. Treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1983; 57: 124-127.
18. Boorman GA, DeLellis RE. C cell hyperplasia, adenoma, carcinoma, thyroid, rat. In Endocrine System, Jones TC (ed). Springer-Verlag: Berlin, Heidelberg, New York, 1983; 192-204.
19. Lausson S, Volle GE, Bourges M, et al. Calcitonin secretion, C cell differentiation and proliferation, during the spontaneous development of murine medullary carcinoma (MTC). Virchows Arch A 1995; 426: 611-616.
20. Zeitinoglu FS, DeLellis RE, Gagel RF, et al. Establishment of a calcitonin-producing rat medullary thyroid carcinoma cell line. I. Morphological studies of the tumor and cells in culture. Endocrinology 1980; 107: 509-515.
21. Lausson S, Fournès B, Borrel C, et al. Immune response against medullary thyroid carcinoma (MTC) induced by parental and/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma. Cancer Immunol Immunother 1996; 43: 116-123.
22. Festing MF. Inbred strains. In The Laboratory Rat: Biology and Diseases, Baker M, Russel L, Weithbross SH (eds). Academic Press: London, 1979; 55-72.
23. Muszynski M, Birnbaum RS, Roos BA. Glucocorticoids stimulate the production of preprocalcitonin-derived secretory peptides by a rat medullary thyroid carcinoma cell line. J Biol Chem 1983; 258: 11678-11683.
24. Berger CL, de Bustros A, Roos BA, et al. Human medullary thyroid carcinoma in culture provides a model relating growth dynamics, endocrine cell differentiation, and tumor progression. J Clin Endocrinol Metab 1984; 59: 338-343.
25. Lyons CR, Orloff GJ, Cunningham JM. Molecular cloning and functional expression of an inducible nitric oxide synthase from a murine macrophage cell line. J Biol Chem 1992; 267: 6370-6375.
26. Nolan C (ed.). Molecular Cloning. A Laboratory Manual (2nd edn). Cold Spring Harbor Laboratory Press: New York, NY, 1989.
27. Gold R, Schmied M, Giegerich G, et al. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 1994; 71: 219-225.
28. Petit JF, Nicaise M, Lepoivre M, et al. Protection by glutathione against the antiproliferative effects of nitric oxide. Biochem Pharmacol 1996; 52: 205-212.
29. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
30. Beck C, Cayeux S, Lupton SD, et al. The thymidine kinase ganciclovir-mediated "suicide" effect is variable in different tumor cells. Hum Gene Ther 1995; 6: 1525-1530.
31. Zhang G, Vargo D, Budker V, et al. Expression of naked plasmid DNA injected into the afferent and efferent vessels of rodent and dog livers. Hum Gene Ther 1997; 8: 1763-1772.
32. Jenkins DC, Charles IG, Thomsen LL, et al. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A 1995; 92: 4392-4396.
33. Corr M, Tighe H, Lee D, et al. Costimulation provided by DNA immunization enhances anti-tumor immunity. J Immunol 1997; 159: 4999-5004.
34. Schreurs MW, de Boer AJ, Figdor CG, et al. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res 1998; 58: 2509-2514.
35. Soubrane C, Mouawad R, Rixe O, et al. Direct gene transfer of a plasmid carrying the herpes simplex virus-thymidine kinase gene (HSVTK) in transplanted murine melanoma: in vivo study. Eur J Cancer 1996; 32A: 691-695.
36. Tan J, Newton CA, Djeu JY, et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res 1996; 56: 3399-3403.
37. Aoki K, Yoshida T, Matsumoto N, et al. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of Herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 8: 1105-1113.
38. Takeshita S, Gal D, Leclerc G, et al. Increased gene expression after liposome-mediated arterial gene transfer associated with intimai smooth muscle cell proliferation. J Clin Invest 1994; 93: 652-661.
39. Vile RG, Russell SJ. Gene transfer technologies for the gene therapy of cancer. Gene Ther 1994; 1: 88-98.
40. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993; 53: 962-967.
41. Barba D, Hardin J, Sadelain M, et al. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A 1994; 91: 4348-4352.
42. Caruso M, Panis Y, Gagandeep S, et al. Regression of established macoscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A 1993; 90: 7024-7028.
43. Vile RG, Nelson JA, Castelden S, et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.